Petal Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 1.25 Cr
- Company Age 38 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 30.92 Cr
- Revenue Growth 87.87%
- Profit Growth -106.69%
- Ebitda 1104.05%
- Net Worth 9.03%
- Total Assets 6.33%
About Petal Pharma
Petal Pharma Private Ltd (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 February 1986 and has a history of 38 years and 11 months. Its registered office is in Delhi, Delhi.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.25 Cr.
The company has closed loans amounting to ₹30.92 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vijay Prakash, Greesh Juneja, Urmila Prakash, and One other member serve as directors at the Company.
Company Details
-
LocationDelhi, Delhi
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74899DL1986PTC023492
-
Company No.
023492
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Feb 1986
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Petal Pharma?
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Vijay Prakash | Director | 11-Apr-2018 | Current |
Greesh Juneja | Director | 11-Apr-2018 | Current |
Urmila Prakash | Director | 01-Dec-1991 | Current |
Anita Juneja | Director | 01-Dec-1991 | Current |
Financial Performance of Petal Pharma.
Petal Pharma Private Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 87.87% increase. The company also saw a substantial fall in profitability, with a 106.69% decrease in profit. The company's net worth moved up by a moderate rise of 9.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Petal Pharma?
Unlock access to Petal Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0
₹30.92 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 16.17 Cr
- Allahabad Bank : 14.75 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
07 Jun 2016 | Hdfc Bank Limited | ₹16.17 Cr | Satisfied |
15 Mar 2007 | Allahabad Bank | ₹14.75 Cr | Satisfied |
How Many Employees Work at Petal Pharma?
Unlock and access historical data on people associated with Petal Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Petal Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Petal Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.